ArticleFrontiers in public health2025
Disease burden and attributable risk factors of major depressive disorder in China, Japan, and South Korea from 1990 to 2021 and its prediction to 2035.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chronic kidney disease due to hypertension in China, Japan, and the Republic of Korea: trends from the Global Burden of Disease Study 1990-2023.International urology and nephrology · 2026Article
- Integrated Microbiome and Metabolomic Profiling to Identify Potential Biomarkers of Major Depressive Disorder.Journal of microbiology and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the disease burden of major depressive disorder (MDD) and risk factors associated with MDD in China, Japan, and South Korea(CJK) from 1990 to 2021, to explore the effects of age, period, and cohort on the disease burden of MDD, and to predict the burden of MDD in CJK from 2021 to 2035. Methods: The Global Burden of Disease 2021 (GBD) database was searched to collect the incidence, prevalence, disability-adjusted life years (DALYs), and risk factors of MDD in CJK. The respondents were selected from the Global, China, Japan, and South Korea. The respondents' disease was major depressive disorder. The respondents' gender was male, female, and both. The time was selected from 1990 to 2021. The age was selected from the whole age group (less than 5 years old to over 95 years old). Trends in MDD burden from 1990 to 2021 were analyzed using Joinpoint 4.9.1.0. Age-period-cohort (APC) analyses were performed using the APC Web Tool. Bayesian age-period-cohort analyses (BAPC) were performed using R4.4.1. Results: Japan had the highest burden of MDD, followed by South Korea, and China had the lowest burden of MDD; The average annual percentage change (AAPC) of MDD burden indicators in China was less than 0, while in Japan and South Korea it was greater than 0. In 2021, middle-aged people aged 55-59 years had the highest burden of MDD in China, while in Japan and South Korea, young people aged 20-29 years had the highest burden of MDD, and the burden of MDD was higher among females than males in CJK from 1990 to 2021; APC analyses showed that the net drifts, local drifts, and RR values of the MDD burden indicators in CJK in terms of age, period, and cohort effects were closely related to the economic forms and aging populations; MDD had 3 levels and 5 risk factors; The burden of MDD in China would be in a decreasing trend between 2021 and 2035, and the burden of MDD in Japan and South Korea would be in a decreasing trend between 2021 and 2022, and an increasing trend between 2022 and 2035. Conclusion: There are both commonalities and differences in the burden of MDD in CJK, while the current burden of MDD in CJK is lower than the global average. Compared with Japan and South Korea China has a lower burden of MDD, but all three countries still face enormous challenges in the prevention and control of MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.